1. Janet Woodcock was born on August 29,1948 and is an American physician who served as Principal Deputy Commissioner of Food and Drugs from February 2022 until February 2024, having previously served as Acting Commissioner of the US Food and Drug Administration.
Janet Woodcock joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research from 1994 to 2004 and 2007 to 2021.
Janet Woodcock informs the United States Congress and other government bodies about the FDA and its concerns, helping to develop policy recommendations and legislation.
Janet Woodcock received a Bachelor of Science in Chemistry from Bucknell University in 1970, and earned her Doctor of Medicine from the Feinberg School of Medicine at Northwestern University Medical School in 1977.
Janet Woodcock worked at the Hershey Medical Center at Pennsylvania State University and the Veterans Administration Medical Center of the University of California, San Francisco, earning certifications in Internal medicine and Rheumatology.
Janet Woodcock joined the US Food and Drug Administration in 1986, as the Director of the Division of Biological Investigational New Drugs in the Center for Biologics Evaluation and Research.
From May 1994 to April 2004 Janet Woodcock served as Director of the Center for Drug Evaluation and Research of the FDA.
From April 2004 to July 2005, Janet Woodcock was Acting Deputy Commissioner for Operations at the FDA.
From October 2007 to March 2008, Janet Woodcock served as Acting Director of the Center for Drug Evaluation and Research.
Janet Woodcock has supported the development of systems which encourage a high degree of participation by consumers, patients, and their advocates.
Janet Woodcock informs Congress and other government bodies about the FDA and its concerns in order to guide policy recommendations and legislation.
Janet Woodcock has testified before congress on at least 50 occasions, under six different US presidents.
In 2000 Janet Woodcock introduced the concept of risk management to the FDA's analysis of drug safety.
Janet Woodcock launched the Sentinel Initiative in 2008 in response to passage of the Food and Drug Administration Amendments Act of 2007.
In 2012 Janet Woodcock oversaw a major reorganization of the generic drug program.